文献速递真菌感染新发突发、热带与寄生虫病医院感染防控

流感相关肺曲霉病的重症监护管理

Intensive care management of influenza-associated pulmonary aspergillosis.
PubMed 文献 · Clin Microbiol Infect · 2019-05-16

本文综述了重症流感相关肺曲霉病在ARDS患者中的管理,检索PubMed至2019年1月。内容涵盖诊断流程(支气管肺泡灌洗、半乳甘露聚糖检测、CT)及治疗(神经氨酸酶抑制剂、艾沙康唑或伏立康唑一线治疗),并强调对无传统真菌感染风险的重症流感患者应提高警惕。

要点

  • 重症流感患者出现呼吸衰竭应警惕流感相关肺曲霉病。
  • 支气管肺泡灌洗液行半乳甘露聚糖检测、镜检、培养及PCR有助诊断。
  • 侵袭性曲霉病一线治疗为艾沙康唑或伏立康唑。

核心结论

  • 流感相关肺曲霉病在无传统真菌感染风险的ARDS患者中报告增多,需提高临床认识。

研究设计与样本

  • 综述,检索PubMed数据库自建库至2019年1月的文献。

主要发现

  • 重症流感肺炎可导致ARDS并并发曲霉感染。
  • 下呼吸道症状患者出现呼吸功能不全应快速全面评估,包括心电图和超声心动图排除心功能障碍、心律失常和缺血。

关键数值与推荐

  • 支气管肺泡灌洗应获取下呼吸道样本行半乳甘露聚糖检测、直接镜检、培养及细菌、真菌和病毒PCR。
  • 曲霉检测阳性时,胸部CT为首选影像学检查。
  • 确诊流感肺炎时,神经氨酸酶抑制剂为首选获批药物。
  • 确诊侵袭性曲霉病时,一线治疗为艾沙康唑或伏立康唑。
  • 对伏立康唑不耐受、药物相互作用、肾功能损害或需覆盖多数毛霉目时,艾沙康唑为替代选择。

临床怎么用

  • 对重症流感合并ARDS患者应警惕流感相关肺曲霉病,行支气管肺泡灌洗和CT检查。
  • 管理算法应包括支气管肺泡灌洗、CT成像、精细呼吸机管理、补救性体外膜氧合及抗真菌和抗病毒治疗。
  • 高危血液病患者推荐泊沙康唑一级抗霉菌预防;新诊断流感和ARDS患者可考虑,但理想情况下应在临床试验中进行。
  • 接种疫苗对减少流感相关疾病负担至关重要,尤其对合并症患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Severe pulmonary infections are among the most common reasons for admission to intensive care units (ICU). Within the last decade, increasing reports of severe influenza pneumonia resulting in acute respiratory distress syndrome (ARDS) complicated by Aspergillus infection were published. OBJECTIVES: To provide a comprehensive review of management of influenza-associated pulmonary aspergillosis in patients with ARDS. SOURCES: Review of the literature pertaining to severe influenza-associated pulmonary aspergillosis. PubMed database was searched for publications from the database inception to January 2019. CONTENT: In patients with lower respiratory symptoms, development of respiratory insufficiency should trigger rapid and thorough clinical evaluation, in particular in cases of suspected ARDS, including electrocardiography and echocardiography to exclude cardiac dysfunction, arrhythmias and ischaemia. Bronchoalveolar lavage should obtain lower respiratory tract samples for galactomannan assay, direct microscopy, culture, and bacterial, fungal and viral PCR. In case of positive Aspergillus testing, chest CT is the imaging modality of choice. If influenza pneumonia is diagnosed, neuraminidase inhibitors are the preferred approved drugs. When invasive aspergillosis is confirmed, first-line therapy consists of isavuconazole or voriconazole. Isavuconazole is an alternative in case of intolerance to voriconazole, drug-drug interactions, renal impairment, or if a spectrum of activity including the majority of Mucorales is desired. Primary anti-mould prophylaxis with posaconazole is recommended in haematology patients at high-risk. It may be considered in newly diagnosed influenza and ARDS, but ideally in clinical trials. IMPLICATIONS: The rising reports of influenza-associated pulmonary aspergillosis in patients with ARDS, who are otherwise not considered at risk for fungal pneumonia demands heightened clinical awareness. Tracheobronchitis and Aspergillus in respiratory tract samples should prompt suspicion of invasive fungal infection and further work-up. The management algorithm should comprise bronchoalveolar lavage, CT imaging, sophisticated ventilator-management, rescue extracorporeal membrane oxygenation, and antifungal and antiviral therapy. To decrease the burden of influenza-related illness, vaccination is of utmost importance, specifically in patients with co-morbidities.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Koehler P, Bassetti M, Kochanek M, et al. Intensive care management of influenza-associated pulmonary aspergillosis. Clin Microbiol Infect. 2019. PMID: 31102782. doi:10.1016/j.cmi.2019.04.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。